<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Loftus SN</submitter><funding>National Institute of Arthritis and Musculoskeletal and Skin Diseases</funding><funding>NIDDK NIH HHS</funding><funding>George M. O&amp;apos;Brien Michigan Kidney Translational Core Center</funding><funding>NIAMS NIH HHS</funding><funding>Arthritis National Research Foundation</funding><pagination>1162799</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10227599</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14</volume><pubmed_abstract>Aberrant activation of the innate immune system is a known driver of lupus pathogenesis. Inhibition of the inflammasome and its downstream signaling components in murine models of lupus has been shown to reduce the severity of disease. Interleukin-1 beta (IL-1β) is a proinflammatory cytokine released from cells following inflammasome activation. Here, we examine how loss of IL-1β affects disease severity in the lupus-prone NZM2328 mouse model. We observed a sex-biased increase in immune complex deposition in the kidneys of female mice in the absence of IL-1β that corresponds to worsened proteinuria. Loss of IL-1β did not result in changes in overall survival, anti-dsDNA autoantibody production, or renal immune cell infiltration. RNA-sequencing analysis identified upregulation of TNF and IL</pubmed_abstract><journal>Frontiers in immunology</journal><pubmed_title>Loss of interleukin-1 beta is not protective in the lupus-prone NZM2328 mouse model.</pubmed_title><pmcid>PMC10227599</pmcid><funding_grant_id>R01-AR071384 , K24AR076975, K01AR072129, UC2 AR081033, P30AR075043</funding_grant_id><funding_grant_id>R01 AR071384</funding_grant_id><funding_grant_id>P30DK081943</funding_grant_id><funding_grant_id>P30 DK081943</funding_grant_id><funding_grant_id>UC2 AR081033</funding_grant_id><funding_grant_id>K01 AR072129</funding_grant_id><funding_grant_id>P30 AR075043</funding_grant_id><funding_grant_id>K24 AR076975</funding_grant_id><pubmed_authors>Kahlenberg JM</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Berthier CC</pubmed_authors><pubmed_authors>Gudjonsson JE</pubmed_authors><pubmed_authors>Loftus SN</pubmed_authors><pubmed_authors>Tsoi LC</pubmed_authors><pubmed_authors>Gharaee-Kermani M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Loss of interleukin-1 beta is not protective in the lupus-prone NZM2328 mouse model.</name><description>Aberrant activation of the innate immune system is a known driver of lupus pathogenesis. Inhibition of the inflammasome and its downstream signaling components in murine models of lupus has been shown to reduce the severity of disease. Interleukin-1 beta (IL-1β) is a proinflammatory cytokine released from cells following inflammasome activation. Here, we examine how loss of IL-1β affects disease severity in the lupus-prone NZM2328 mouse model. We observed a sex-biased increase in immune complex deposition in the kidneys of female mice in the absence of IL-1β that corresponds to worsened proteinuria. Loss of IL-1β did not result in changes in overall survival, anti-dsDNA autoantibody production, or renal immune cell infiltration. RNA-sequencing analysis identified upregulation of TNF and IL</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-05-29T14:01:54.475Z</modification><creation>2024-11-13T04:03:46.148Z</creation></dates><accession>S-EPMC10227599</accession><cross_references><pubmed>37261358</pubmed><doi>10.3389/fimmu.2023.1162799</doi></cross_references></HashMap>